RCMT

Business Context and Reporting Period

Company: RCM Technologies, Inc. (RCMT)

Filing Type: Form 10-K (Annual Report)

Reporting Period: Fiscal year ended January 3, 2026 (53 weeks).

Business Overview: RCM is a provider of business and technology solutions, operating through three segments: Specialty Health Care (51.4% of revenue), Engineering (37.7%), and Life Sciences, Data and Solutions (10.9%). The company serves healthcare institutions, engineering firms, and life sciences companies across North America and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 14.7% ($41.0 million) driven by growth in Specialty Health Care (+15.0%) and Engineering (+24.9%). The Life Sciences, Data and Solutions segment declined 11.3% due to project timing and a strategic deemphasis on legacy staffing.
• Profitability: Net income rose 22.6% to $16.3 million. The effective tax rate decreased from 34.0% to 26.0%, primarily due to a change in unrecognized tax benefits in the U.S.
• Segment Performance:
  • Specialty Health Care: Revenue grew to $164.1 million, driven by school clients, though non-school revenue declined due to lost contracts.
  • Engineering: Revenue reached $120.5 million, fueled by Energy Services (EPC projects) and Aerospace expansion.
  • Life Sciences: Revenue dropped to $34.8 million.
• Cash Flow: Operating cash flow improved significantly to $19.0 million, aided by a $10.6 million increase in deferred revenue from upfront EPC contract payments.
• Capital Allocation: The company repurchased 416,582 shares of treasury stock for $7.4 million during the fiscal year.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management expects continued demand for outsourcing in AI, Quality by Design (QbD), and process automation. The company is focused on transitioning to higher-value services to improve margins.
• Unusual Items:
  • Contingent Consideration: In the prior year (2024), the company recorded a $1.8 million benefit from the remeasurement of contingent consideration. No such item occurred in 2025.
  • Intangible Assets: In 2024, the company recorded a $0.5 million impairment of intangible assets. No impairment was recorded in 2025.
• Risks and Contingencies:
  • Customer Concentration: Two customers accounted for 20.8% and 13.6% of total revenue in 2025. The top 20 customers represented 75.0% of revenue.
  • Internal Controls: The company identified material weaknesses in internal control over financial reporting, resulting in an adverse opinion from its auditor (EisnerAmper LLP). Weaknesses included deficiencies in entity-level controls, management review documentation, and IT change management. Remediation is in progress.
  • Geopolitical: Operations in Serbia face potential risks related to the conflict between Ukraine and Russia.
  • Cybersecurity: The company faces ongoing risks of cyber attacks, though no material incidents were reported in the period.

Investor Verification Checklist

• Internal Control Remediation: Verify the progress and timeline for remediation of the material weaknesses in internal controls identified by management and the auditor.
• Customer Concentration: Assess the stability of the top two customers (representing ~34% of revenue) and the impact of potential contract losses.
• Deferred Revenue Quality: Review the composition of the $14.8 million deferred revenue balance (up from $4.2 million) to ensure it represents sustainable future earnings, particularly regarding EPC project timing.
• Segment Mix Shift: Monitor the continued decline in the Life Sciences segment and the company's ability to offset this with growth in Engineering and Health Care.
• Debt Covenants: Confirm ongoing compliance with the Revolving Credit Facility covenants, particularly given the material weaknesses in financial reporting.